Shanghai, China, September 24, 2026
Henlius has announced a strategic partnership with Amberstone Biosciences to discover and develop next-generation conditionally activated T-cell engagers (TCEs) for the treatment of solid tumors. The collaboration combines Henlius’ expertise in bispecific antibody development and oncology with Amberstone’s technology platforms for developing conditionally activated biologics. The companies aim to create TCE candidates designed to selectively activate immune responses within the tumor microenvironment while reducing activity in healthy tissues. T-cell engagers are a growing class of cancer immunotherapies designed to bring T cells into close proximity with tumor cells, enabling the immune system to recognize and eliminate malignant cells. However, developing TCEs for solid tumors presents challenges associated with on-target, off-tumor activity, systemic immune activation and tumor heterogeneity. Through the new collaboration, Henlius and Amberstone intend to address these challenges by applying conditional activation strategies to the development of novel TCE therapeutics.
Henlius and Amberstone Target Solid Tumors
The partnership will focus on discovering conditionally activated TCEs intended for solid tumor indications. Conventional TCEs can activate T cells when their binding domains engage their respective targets, but uncontrolled activation outside the tumor environment can potentially create safety challenges. Conditional activation technologies are designed to keep therapeutic molecules in a less active state until they encounter specific conditions associated with the tumor microenvironment. This approach could potentially improve the therapeutic window by concentrating immune activity where it is needed. Henlius and Amberstone will combine their respective capabilities to identify and develop TCE molecules that can address these challenges while maintaining the ability to engage tumor-associated targets and recruit T cells.
Next-Generation TCEs Aim to Improve Safety
A major focus of the collaboration is the development of tumor-selective immune activation. Solid tumors can express therapeutic targets at different levels across tumor cells and normal tissues, making target selection and antibody engineering particularly important. Conditional activation provides a potential strategy for reducing unwanted systemic activity by engineering a molecule whose activity is controlled by the local tumor environment. Such approaches can include mechanisms that exploit differences between tumor and healthy tissue environments. For TCEs, this strategy could potentially allow the therapeutic molecule to remain relatively inactive during circulation and become activated after reaching the tumor. The companies’ research will evaluate whether this approach can generate candidates with improved selectivity and therapeutic characteristics.
Advertisement
Combining Antibody and Biologic Discovery Expertise
Henlius brings experience in antibody-based drug development, bispecific antibodies and oncology therapeutics to the partnership. The company has developed a broad pipeline of innovative biologics and has established capabilities spanning discovery, clinical development, manufacturing and commercialization. Amberstone Biosciences contributes specialized expertise in antibody discovery and engineering, including technologies intended to develop biologics with controlled activity. By combining these capabilities, the companies aim to accelerate the discovery of TCE candidates designed specifically for the biological challenges presented by solid tumors. The collaboration represents an example of how pharmaceutical and biotechnology companies are increasingly combining complementary technology platforms to advance complex immuno-oncology therapeutics.
TCEs have emerged as an important area of cancer drug development because they can directly connect immune effector cells with malignant cells. While T-cell engagers have demonstrated clinical utility in certain hematological malignancies, extending the approach to solid tumors remains an active area of research. The tumor microenvironment, target accessibility, antigen heterogeneity and potential toxicity associated with systemic immune activation all create development challenges. Henlius and Amberstone’s focus on conditional activation is intended to address some of these barriers by developing molecules with greater control over where and when immune activation occurs. The partnership remains at the discovery and development stage, and any resulting candidates will need to undergo preclinical and clinical testing before their safety and efficacy can be established. The collaboration expands Henlius’ activities in next-generation immuno-oncology and provides Amberstone with an opportunity to apply its technology to a broad range of solid tumor targets. The companies’ work will focus on discovering and developing conditionally activated TCEs, with the ultimate objective of generating new therapeutic candidates for patients with solid tumors. As research continues, preclinical data will be important for determining whether the engineered molecules can achieve the intended combination of tumor selectivity, T-cell activation and safety. The partnership highlights continued innovation in bispecific antibodies and T-cell engager technology as researchers seek new approaches for overcoming the biological complexity of solid cancers.
Source: Henlius, Amberstone Biosciences press release
